Medical Condition News

RSS

FDA grants marketing clearance to Accuray's CyberKnife VSI System Lung Optimized Treatment

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market Lung Optimized Treatment, a new component of the CyberKnife® VSI™ System. The 510(k) clearance enables Accuray to provide physicians with greater flexibility in delivering radiosurgery treatments to patients with lung cancer, the most common and deadly cancer worldwide.

15 Dec 2010

Scientists discover potential strategy for pancreatic cancer therapy

By determining what goes missing in human cells when the gene that is most commonly mutated in pancreatic cancer gets turned on, Johns Hopkins scientists have discovered a potential strategy for therapy.

15 Dec 2010

Experts study obesity in young population with physical, cognitive disabilities

While the nation's obesity epidemic is the target of many programs to combat it, few such programs embrace an often-overlooked subgroup adolescents and young adults with physical or cognitive disabilities.

15 Dec 2010

Almonds can help treat, prevent type 2 diabetes and cardiovascular disease

With nearly 16 million Americans living today with pre-diabetes, a condition that is the precursor to type 2 diabetes, and half of all Americans expected to have some form of diabetes by the year 2020, healthy eating is more important than ever. But here is some good news: a recent scientific study shows that incorporating almonds into your diet can help treat and possibly prevent type 2 diabetes, as well as cardiovascular disease.

15 Dec 2010

MDA supports Repligen with $1.4M grant for RG3039 Spinal Muscular Atrophy development program

Repligen Corporation today announced that the Company has received $1,400,000 in research funding from the Muscular Dystrophy Association ("MDA") to support the ongoing development of RG3039 for Spinal Muscular Atrophy ("SMA"). RG3039, our lead compound, is an inhibitor of an RNA processing enzyme which targets increased production of SMN, a protein of deficient levels in patients with SMA.

15 Dec 2010

iTech Medical receives CE Mark approval for Muscle Pattern Recognition System

iTech Medical, Inc., a medical information technology company, announced today that it has received CE Mark approval for the commercial sale of the Company's Muscle Pattern Recognition (MPR) System in Europe. This approval allows for the marketing and sale of the device in the European Union (EU) and all countries recognizing the CE Mark.

15 Dec 2010

Targeting mutant BRAF can kill cancer cells, but cannot finish off melanoma

This past summer saw a revolution in melanoma therapy. Patients whose melanoma lesions contain a mutation in the BRAF gene were successfully treated with a BRAF-specific inhibitor, PLX4032. Reports of the drug trial described shrinking tumors and improved health. Yet seven months after therapy began the tumors returned and resumed growing. Now, scientists at The Wistar Institute explain why: the tumor learns to signal around the blocked gene by adjusting its molecular wiring.

15 Dec 2010

SBUMC to rename and dedicate ALS clinic as Christopher Pendergast ALS Center of Excellence

For Chris Pendergast, every Christmas he has been alive to celebrate with his family for the past 17 years has been a gift unto itself. Indeed, in 1993 the then 44-year-old elementary school teacher from Miller Place on Long Island was diagnosed with amyotrophic lateral sclerosis - ALS - the always fatal degenerative neuromuscular disease commonly known as Lou Gehrig's Disease. He was told that he had, at best, three to five years to live.

15 Dec 2010

Charité begins implementation of MGN1601 clinical phase I/II study in renal cancer

The Charité - Medical University of Berlin has today begun the implementation of the clinical study phase I/II with the renal cancer medication MGN1601 (ASET Study). With this MOLOGEN AG product, an innovative cell-based gene therapy for the treatment of advanced renal cancer is entering the first important test phase.

15 Dec 2010

Lung protective strategy after brain death doubles lungs eligible for donation

Use of certain measures for lung preservation after brain death in potential organ donors resulted in a nearly doubling of lungs eligible for donation, compared to a conventional strategy that is used, according to preliminary research published in the December 15 issue of JAMA.

15 Dec 2010

Develogen enters license, collaboration agreement with MedImmune on insulin beta cell regeneration

Evotec AG today announced that via its subsidiary Develogen AG it has entered into a license and collaboration agreement with MedImmune (the global biologics unit of AstraZeneca), in the diabetes therapeutic area, with a particular focus on the regeneration of insulin producing beta cells. The license gives MedImmune exclusive access to a portfolio of research programs and represents the first deal executed by Evotec on beta cell regeneration assets and capabilities.

15 Dec 2010

MDMA produces friendliness, playfulness, and loving feelings in laboratory setting

MDMA or 'ecstasy' increases feelings of empathy and social connection. These 'empathogenic' effects suggest that MDMA might be useful to enhance the psychotherapy of people who struggle to feel connected to others, as may occur in association with autism, schizophrenia, or antisocial personality disorder.

15 Dec 2010

RPCI forms Photolitec to develop photosensitizing compounds used in photodynamic therapy

Roswell Park Cancer Institute (RPCI) on December 13, 2010, announced the formation of Photolitec, LLC, a new life-sciences company at RPCI that will develop photosensitizing compounds used in photodynamic therapy (PDT). PDT is an innovative cancer treatment pioneered at RPCI by scientist Thomas J. Dougherty, Chief Emeritus of the Institute's Photodynamic Therapy Center.

15 Dec 2010

New online tools allow parents with autistic children to enjoy holiday season

Rethink Autism, an educational technology company that produces online research-based treatment tools for parents and professionals, offers some suggestions and a free online set of video tips to help families address some of these challenges and enjoy the holidays.

15 Dec 2010

Yorkshire Cancer Research to grant over GBP1.26 million for research at universities of Leeds and Sheffield

Yorkshire Cancer Research (YCR) is set to give more than GBP1.26 million of funding to researchers at the universities of Leeds and Sheffield next year.

15 Dec 2010

CTT, Bayer sign Research and License Option Agreement

Cancer Targeted Technology (CTT), a Seattle-based biotechnology firm focusing on small molecule cancer enzyme inhibitors for the generation of novel diagnostics and therapeutics, today announced that it has signed a Research and License Option Agreement with Bayer Pharma AG, Germany. Under the agreement, CTT will work with Bayer to optimize a novel PET imaging agent based on its unique inhibitor scaffold that recognizes a validated cancer enzyme biomarker.

15 Dec 2010

Research reveals pattern of declining health among Mexican-American immigrants

Mexican-Americans who are most integrated into the culture including those born in the United States, and not recent immigrants appear less healthy and more likely to require resources to manage their health conditions than more recent, less-integrated migrants, according to a new study from Rice University, Duke University and the University of Colorado Denver.

15 Dec 2010

Anoles key to medically applicable regeneration?

Anolis lizards first entered Arizona State University biologist Kenro Kusumi's life in 1980 when, as a member of a junior curator program, he recorded in his field notebook that he had found an Anolis egg on a field trip. Kusumi still has those notes, along with other memorabilia that document the influence that both his early life and more recent experiences have had on his current pursuits in developmental biology.

15 Dec 2010

Researchers examine expression of toxic mRNA in patients with Fragile X Tremor Ataxia Syndrome

Expression of a toxic RNA that leads to Fragile X Tremor Ataxia Syndrome is modifiable by genetic or pharmacologic means, according to new research from U-M Medical School scientists.

15 Dec 2010

Naltrexone may help treat alcoholism

A little-used medication can help treat alcoholism, an updated review of studies confirms.

15 Dec 2010

Medical Condition News

FDA grants marketing clearance to Accuray's CyberKnife VSI System Lung Optimized Treatment

Scientists discover potential strategy for pancreatic cancer therapy

Experts study obesity in young population with physical, cognitive disabilities

Almonds can help treat, prevent type 2 diabetes and cardiovascular disease

MDA supports Repligen with $1.4M grant for RG3039 Spinal Muscular Atrophy development program

iTech Medical receives CE Mark approval for Muscle Pattern Recognition System

Targeting mutant BRAF can kill cancer cells, but cannot finish off melanoma

SBUMC to rename and dedicate ALS clinic as Christopher Pendergast ALS Center of Excellence

Charité begins implementation of MGN1601 clinical phase I/II study in renal cancer

Lung protective strategy after brain death doubles lungs eligible for donation

Develogen enters license, collaboration agreement with MedImmune on insulin beta cell regeneration

MDMA produces friendliness, playfulness, and loving feelings in laboratory setting

RPCI forms Photolitec to develop photosensitizing compounds used in photodynamic therapy

New online tools allow parents with autistic children to enjoy holiday season

Yorkshire Cancer Research to grant over GBP1.26 million for research at universities of Leeds and Sheffield

CTT, Bayer sign Research and License Option Agreement

Research reveals pattern of declining health among Mexican-American immigrants

Anoles key to medically applicable regeneration?

Researchers examine expression of toxic mRNA in patients with Fragile X Tremor Ataxia Syndrome

Naltrexone may help treat alcoholism

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News